Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2022 | Migraine | Review article

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies

Authors: Janu Thuraiaiyah, Lili Kokoti, Mohammad Al-Mahdi Al-Karagholi, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Background

Adenosine is a purinergic signaling molecule with a wide range of physiological functions including anti- and pronociceptive properties. Adenosine receptors are expressed in the trigeminovascular system, and adenosine receptor antagonist, caffeine, relieves migraine headache. We performed a systematic review of the literature of preclinical data addressing the role of adenosine in migraine pathophysiology.

Methods

PubMed and EMBASE were searched for pre-clinical studies on the role of adenosine in migraine pathophysiology on September 5^th, 2021.

Results

A total of 2510 studies were screened by title and abstract. Of these, thirteen pre-clinical studies evaluating adenosine, adenosine A1, A2A and A3 receptors were included.

These studies showed that adenosine signaling pathway is involved in controlling vascular tone. Furthermore, electrical stimulation of the trigeminal ganglion modulates the expression of adenosine A₁ and A_2A receptors in the trigeminal ganglion and trigeminal nucleus caudalis implicating adenosine signaling pathway in pain transmission.

Conclusion

Preclinical studies showed that adenosine has a dual effect on vasodilation and trigeminal pain pathway due to different receptor activation, suggesting a possible role of adenosine in migraine pathophysiology. Studies investigating pharmacological characteristics of subtypes of adenosine receptors are needed to further elucidate their role as a potential target for migraine treatment.

Arulmani U, Heiligers JPC, Centurión D et al (2005) Lack of effect of the adenosine A1 receptor agonist, GR79236, on capsaicin-induced CGRP release in anaesthetized pigs. Cephalalgia. https://doi.org/10.1111/j.1468-2982.2005.00967.xCrossRefPubMed

Ashina M (2020) Migraine. N Engl J Med 383:1866–1876. https://doi.org/10.1056/NEJMra1915327CrossRefPubMed

Baxter GF, Hale SL, Miki T et al (2000) Adenosine A1 agonist at reperfusion trial (AART): Results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14:607–614. https://doi.org/10.1023/A:1007850527878CrossRefPubMed

Borea PA, Gessi S, Merighi S et al (2018) Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev 98:1591–1625. https://doi.org/10.1152/physrev.00049.2017.-AdenosineCrossRefPubMed

Carley DW, Hagan RM, Sheehan M et al (1997) Adenosine A1 receptor agonist GR79236 suppresses apnea during all sleep stages in the rat. Sleep 20:1093–1098. https://doi.org/10.1093/sleep/20.12.1093CrossRefPubMed

Carruthers AM, Sellers LA, Jenkins DW et al (2001) Adenosine A1 receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol 59:1533–1541. https://doi.org/10.1124/mol.59.6.1533CrossRefPubMed

Chou SY, Lee YC, Chen HM et al (2005) CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model. J Neurochem 93:310–320. https://doi.org/10.1111/j.1471-4159.2005.03029.xCrossRefPubMed

Dastjerdi MN, Rarani MZ, Valiani A, Mahmoudieh M (2016) The effect of adenosine A1 receptor agonist and antagonist on p53 and caspase 3, 8, and 9 expression and apoptosis rate in MCF-7 breast cancer cell line. Res Pharm Sci 11:303–310. https://doi.org/10.4103/1735-5362.189301CrossRefPubMedPubMedCentral

Faraci FM, Kadel KA, Heistad DD (1989) Vascular responses of dura mater. Am J Physiol - Hear Circ Physiol 257:H157-61. https://doi.org/10.1152/ajpheart.1989.257.1.h157CrossRef

10.

Faudone G, Arifi S, Merk D (2021) The Medicinal Chemistry of Caffeine. J Med Chem 64:7156–7178. https://doi.org/10.1021/ACS.JMEDCHEM.1C00261CrossRefPubMed

11.

Fried NT, Elliott MB, Oshinsky ML (2017) The Role of Adenosine Signaling in Headache: A Review. Brain Sci 7:30. https://doi.org/10.3390/brainsci7030030CrossRefPubMedCentral

12.

Giffin NJ, Kowacs F, Libri V et al (2003) Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 23:287–292. https://doi.org/10.1046/j.1468-2982.2003.00511.xCrossRefPubMed

13.

Goadsby PJ, Hoskin KL, Storer RJ et al (2002) Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125:1392–1401. https://doi.org/10.1093/brain/awf141CrossRefPubMed

14.

González-Fernández E, Sánchez-Gómez MV, Pérez-Samartín A et al (2014) A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. Glia 62:199–216. https://doi.org/10.1002/glia.22599CrossRefPubMed

15.

Haanes KA, Edvinsson L (2014) Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine. PLoS One 9(9):e108782–e108782. https://doi.org/10.1371/journal.pone.0108782

16.

Haanes KA, Labastida-Ramírez A, Chan KY et al (2018) Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine. J Headache Pain 19:1–10. https://doi.org/10.1186/s10194-018-0867-xCrossRef

17.

Hardebo JE, Edvinsson L (1979) Adenine compounds: Cerebrovascular effects In Vitro with reference to their possible involvement in migraine. Stroke. https://doi.org/10.1161/01.STR.10.1.58CrossRefPubMed

18.

Heseltine L, Webster JM, Taylor R (1995) Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes. Mol Cell Biochem 144:147–151. https://doi.org/10.1007/BF00944394CrossRefPubMed

19.

Honey AC, Bland-Ward PA, Connor HE et al (2002) Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Cephalalgia 22:260–264. https://doi.org/10.1046/j.1468-2982.2002.00345.xCrossRefPubMed

20.

Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247–264. https://doi.org/10.1038/nrd1983CrossRefPubMedPubMedCentral

21.

Jacobson KA, Tosh DK, Jain S, Gao ZG (2019) Historical and current adenosine receptor agonists in preclinical and clinical development. Front Cell Neurosci 13:1–17. https://doi.org/10.3389/fncel.2019.00124CrossRef

22.

Jenkins DW, Feniuk W, Humphrey PPA (2001) Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 134:1296–1302. https://doi.org/10.1038/sj.bjp.0704357CrossRefPubMedPubMedCentral

23.

Chen JF, Cunha RA (2020) The belated US FDA approval of the adenosine A 2A receptor antagonist istradefylline for treatment of Parkinson’s disease. Purinergic Signal 16:167–174. https://doi.org/10.1007/S11302-020-09694-2CrossRefPubMedPubMedCentral

24.

Little JW, Ford A, Symons-Liguori AM et al (2015) Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain 138:28–35. https://doi.org/10.1093/BRAIN/AWU330CrossRefPubMed

25.

Kelion AD, Webb TP, Gardner MA et al (2002) Does a selective adenosine A1 receptor agonist protect against exercise induced ischaemia in patients with coronary artery disease? Heart 87:115–120. https://doi.org/10.1136/heart.87.2.115CrossRefPubMedPubMedCentral

26.

Kirsch GE, Codina J, Birnbaumer L, Brown AM (1990) Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytesCrossRef

27.

Kleppisch T, Nelson MT (1995) Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A2 receptors and cAMP-dependent protein kinase (vasodilation/glibenclamide/hypoxia/P1 receptors)

28.

Kunduri S, Dick G, Nayeem M, Mustafa S (2013) Adenosine A(1) receptor signaling inhibits BK channels through a PKCα-dependent mechanism in mouse aortic smooth muscle. Physiol Rep 1:e00037. https://doi.org/10.1002/phy2.37CrossRefPubMedPubMedCentral

29.

Li M, Kang R, Shi J et al (2013) Anticonvulsant Activity of B2, an Adenosine Analog, on Chemical Convulsant-Induced Seizures. PLoS ONE 8:67060. https://doi.org/10.1371/journal.pone.0067060CrossRef

30.

Lin Z, Yin P, Reierstad S et al (2010) Adenosine A1 receptor, a target and regulator of estrogen receptorα action, mediates the proliferative effects of estradiol in breast cancer. Oncogene 29:1114–1122. https://doi.org/10.1038/onc.2009.409CrossRefPubMed

31.

Lindquist BE, Shuttleworth CW (2014) Spreading depolarization-induced adenosine accumulation reflects metabolic status in vitro and in vivo. J Cereb Blood Flow Metab 34:1779–1790. https://doi.org/10.1038/jcbfm.2014.146CrossRefPubMedPubMedCentral

32.

Lu W, Li B, Chen J et al (2016) Expression of calcitonin gene-related peptide, adenosine A2a receptor and adenosine A1 receptor in experiment rat migraine models. Biomed Reports 4:379–383. https://doi.org/10.3892/br.2016.591CrossRef

33.

Mediero A, Wilder T, Perez-Aso M, Cronstein BN (2015) Direct or indirect stimulation of adenosine A2Areceptors enhances bone regeneration as well as bone morphogenetic protein-2. FASEB J 29:1577–1590. https://doi.org/10.1096/fj.14-265066CrossRefPubMedPubMedCentral

34.

Nowaczewska M, Wiciński M, Kaźmierczak W (2020) The Ambiguous Role of Caffeine in Migraine Headache: From Trigger to Treatment. Nutrients 12:1–16. https://doi.org/10.3390/NU12082259CrossRef

35.

Ocaña M, Baeyens JM (1994) Role of ATP-sensitive K+ channels in antinociception induced by R-PIA, an adenosine A1 receptor agonist. Naunyn Schmiedebergs Arch Pharmacol 350:57–62. https://doi.org/10.1007/BF00180011CrossRefPubMed

36.

Paterniti I, Melani A, Cipriani S et al (2011) Selective adenosine A2Areceptor agonists and antagonists protect against spinal cord injury through peripheral and central effects. J Neuroinflammation 8:1–14. https://doi.org/10.1186/1742-2094-8-31CrossRef

37.

Ragozzino D, Limatola C, Sobrero F et al (2021) Hippocampal Neurons Neuroprotection and Neuromodulation in CL1-Mediated 3 Required for CX Activity of Adenosine Receptors Type 1 Is. J Immunol Ref 180:7590–7596. https://doi.org/10.4049/jimmunol.180.11.7590CrossRef

38.

Sachdeva S, Gupta M (2013) Adenosine and its receptors as therapeutic targets: An overview. Saudi Pharm J 21:245–253. https://doi.org/10.1016/j.jsps.2012.05.011CrossRefPubMed

39.

Sawynok J (2016) Adenosine receptor targets for pain. Neuroscience 338:1–18CrossRef

40.

Shen WT, Huang YJ, Zhang Q et al (2020) SCH58261, the antagonist of adenosine A2A receptor, alleviates cadmium-induced preeclampsia via sirtiun-1/hypoxia-inducible factor-1a pathway in rats. Eur Rev Med Pharmacol Sci 24:10941–10953. https://doi.org/10.26355/eurrev_202011_23577CrossRefPubMed

41.

Sneyd RJ, Langton JA, Allan LG et al (2007) Multicentre evaluation of the adenosine agonist GR79236X in patients with dental pain after third molar extraction. Br J Anaesth 98:672–676. https://doi.org/10.1093/bja/aem075CrossRefPubMed

42.

Szopa A, Poleszak E, Bogatko K et al (2018) DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests. Naunyn Schmiedebergs Arch Pharmacol 391:1361. https://doi.org/10.1007/s00210-018-1551-zCrossRefPubMedPubMedCentral

43.

Tabrizchi R, Bedi S (2001) Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 91:133–147CrossRef

44.

Teoh LKK, Grant R, Hulf JA et al (2002) The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res 53:175–180. https://doi.org/10.1016/S0008-6363(01)00435-7CrossRefPubMed

45.

Thuraiaiyah J, Kokoti L, Al-Karagholi MA, Ashina M (2022) Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies. Cephalalgia. https://doi.org/10.1177/03331024221077665.

46.

Wei EP, Moskowitz MA, Boccalini P, Kontos HA (1992) Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. Circ Res 70:1313–1319. https://doi.org/10.1161/01.RES.70.6.1313CrossRefPubMed

47.

Yang Y, Zhang H, Lu Q et al (2021) Suppression of adenosine A2a receptors alleviates bladder overactivity and hyperalgesia in cyclophosphamide-induced cystitis by inhibiting TRPV1. Biochem Pharmacol 183:114340. https://doi.org/10.1016/j.bcp.2020.114340CrossRefPubMed

48.

Yegutkin GG, Guerrero-Toro C, Kilinc E et al (2016) Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions. Purinergic Signal 12:561–574. https://doi.org/10.1007/s11302-016-9521-8CrossRefPubMedPubMedCentral

49.

Yuan K, Bai GY, Park WH et al (2008) Stimulation of ANP secretion by 2-Cl-IB-MECA through A3 receptor and CaMKII. Peptides 29:2216–2224. https://doi.org/10.1016/j.peptides.2008.09.003CrossRefPubMed

50.

Zhou Y, Tong L, Chu X et al (2017) The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma. Cell Physiol Biochem 43:733–742. https://doi.org/10.1159/000481557CrossRefPubMed

Title: Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies
Authors: Janu Thuraiaiyah
Lili Kokoti
Mohammad Al-Mahdi Al-Karagholi
Messoud Ashina
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Migraine
Headache
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-022-01412-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Time is of the essence in headache measurement. A response to Gil-Gouveia

The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients

Tracking the evolution of non-headache symptoms through the migraine attack

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients

Narrative-based medicine in headache disorders